Mesoblast Limited (NASDAQ:MESO - Get Free Report) was up 6.1% during mid-day trading on Thursday . The company traded as high as $18.07 and last traded at $18.06. Approximately 92,091 shares changed hands during mid-day trading, a decline of 88% from the average daily volume of 738,914 shares. The stock had previously closed at $17.02.
Analyst Ratings Changes
A number of equities analysts have recently issued reports on MESO shares. Cantor Fitzgerald reiterated an "overweight" rating on shares of Mesoblast in a research note on Thursday, August 29th. StockNews.com lowered Mesoblast from a "hold" rating to a "sell" rating in a research note on Wednesday, September 4th. Maxim Group upgraded shares of Mesoblast from a "hold" rating to a "buy" rating and set a $12.00 price objective for the company in a research note on Tuesday, September 24th. Piper Sandler upped their target price on Mesoblast from $11.00 to $15.00 and gave the stock an "overweight" rating in a research note on Thursday, December 19th. Finally, Jefferies Financial Group lowered shares of Mesoblast from a "buy" rating to a "hold" rating in a research report on Monday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Mesoblast currently has a consensus rating of "Hold" and an average price target of $13.50.
View Our Latest Stock Report on Mesoblast
Mesoblast Stock Performance
The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21. The company has a fifty day moving average of $10.92 and a 200-day moving average of $8.50.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Pine Valley Investments Ltd Liability Co acquired a new stake in Mesoblast in the 2nd quarter valued at about $80,000. Rathbones Group PLC purchased a new stake in shares of Mesoblast in the second quarter valued at approximately $95,000. XTX Topco Ltd acquired a new stake in shares of Mesoblast in the second quarter valued at approximately $103,000. Marshall Wace LLP purchased a new position in Mesoblast during the second quarter worth approximately $562,000. Finally, Lazari Capital Management Inc. boosted its stake in Mesoblast by 6.6% during the second quarter. Lazari Capital Management Inc. now owns 53,467 shares of the company's stock worth $364,000 after buying an additional 3,300 shares during the last quarter. Hedge funds and other institutional investors own 1.43% of the company's stock.
Mesoblast Company Profile
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
See Also
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
